NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 3, 2017, J. Peter Wolf, General Counsel and Corporate Secretary of Nabriva Therapeutics AG (the “Company”) notified the Company that he will resign from his positions, effective February 7, 2017, to pursue other opportunities. The Company has commenced a search for Mr. Wolf’s successor.
Item 7.01 Regulation FD Disclosure.
The Company intends to meet with investors and analysts over the course of the next several weeks. A copy of the materials to be presented at these meetings is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 7.01. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
See Exhibit Index attached hereto.